MedPage Today - "Little Risk When Doc Says Stop DAPT"

Dual antiplatelet therapy is once again a hot-line focus at the European Society of Cardiology - but this time the message is a reassuring one for both patients and physicians: doctor knows best.

New York, NY
 – September 1, 2013  –– 

Roxana Mehran, MD, of the Icahn School of Medicine at Mount Sinai, said that in a prospective, observational study of more than 5000 stent patients, physician-guided discontinuation of dual antiplatelet therapy was associated with a "substantially lower MACE [major adverse cardiac event] risk."

- Dr. Roxana Mehran, Professor, Medicine, Cardiology, Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai

Learn More